PCMV hides in latency and passes through donor screening
biotechbiotech0 views
Porcine cytomegalovirus (PCMV) establishes lifelong latent infections in pig donors, and in the latent stage the viral load drops below PCR detection limits. This means a donor pig can test negative on nasal swabs and blood PCR, be cleared for transplant, and still carry latent PCMV in organ tissue. This is exactly what happened in David Bennett's pig heart transplant in 2022: the donor pig tested negative, but after transplant PCMV was found in his bloodstream. The clinical team then administered intravenous immunoglobulin (IVIG) to treat it, but the IVIG batch unknowingly contained high levels of xenoantibodies, which may have triggered the acute antibody-mediated rejection that killed him. So the screening failure cascaded: undetected virus led to an intervention that introduced new antibodies that attacked the graft. This persists because PCMV integrates into host cell DNA and goes dormant, making it fundamentally invisible to any assay that looks for active viral replication. There is no validated clinical-grade test that reliably detects PCMV during latency across all tissue types, and current screening protocols rely on nasal swabs and blood PCR, which miss tissue-resident latent virus.
Evidence
In a study of 20 pig-to-cynomolgus kidney xenotransplants, 4 recipients tested PCMV-positive despite donor-negative screening (Denner, 2024, Wiley Xenotransplantation). In Bennett's case, post-mortem analysis confirmed PCMV in the transplanted heart despite negative pre-transplant donor screening (Griffith et al., NEJM 2022). A 2022 Nature Scientific Reports paper titled 'How, where and when to screen for PCMV in donor pigs' concluded that a combination of PCR and immunological methods is necessary but no single protocol reliably catches latent infections.